Lifecore Biomedical Analyst Ratings
Lifecore Biomedical Analyst Ratings
While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a maintained with a price target of $8.00 to $9.00. The current price Lifecore Biomedical (LFCR) is trading at is $7.89, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | Stephens & Co. | $8 → $9 | Maintains | Equal-Weight |
| 06/02/2023 | 39.42% | Barrington Research | $10 → $11 | Maintains | Outperform |
| 05/24/2023 | 26.74% | Barrington Research | $8 → $10 | Maintains | Outperform |
| 03/21/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | -74.65% | Stephens & Co. | $11 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/17/2023 | 39.42% | Stephens & Co. | → $11 | Reiterates | → Overweight |
| 日期 | 上行/下行空間 | 分析師公司 | 價格目標變更 | 評級變化 | 之前/現今評級 |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | Stephens & Co. | $8→$9 | Maintains | 中性權重 |
| 06/02/2023 | 39.42% | Barrington研究 | $10 → $11 | Maintains | Outperform |
| 05/24/2023 | 26.74% | Barrington研究 | 8美元 → 10美元 | Maintains | Outperform |
| 03/21/2023 | 1.39% | Barrington研究 | $10 變成 $8 | Maintains | Outperform |
| 03/20/2023 | 1.39% | Barrington研究 | $10 變成 $8 | Maintains | Outperform |
| 03/20/2023 | -74.65% | Stephens & Co. | $11變爲$2 | Downgrades | 增持 → 持平 |
| 03/17/2023 | 39.42% | Stephens & Co. | → $11 | Reiterates | → Overweight |
What is the target price for Lifecore Biomedical (LFCR)?
Lifecore生物醫藥（LFCR）的目標價是多少？
The latest price target for Lifecore Biomedical (NASDAQ: LFCR) was reported by Stephens & Co. on September 1, 2023. The analyst firm set a price target for $9.00 expecting LFCR to rise to within 12 months (a possible 14.07% upside). 7 analyst firms have reported ratings in the last year.
Lifecore生物醫藥（納斯達克：LFCR）的最新目標價由史蒂芬斯及公司於2023年9月1日報告。分析師公司設定了9.00美元的目標價，預計LFCR在12個月內將上漲（可能會增長14.07%）。過去一年中有7家分析師公司報告了評級。
What is the most recent analyst rating for Lifecore Biomedical (LFCR)?
Lifecore生物醫藥（LFCR）最近的分析師評級是什麼？
The latest analyst rating for Lifecore Biomedical (NASDAQ: LFCR) was provided by Stephens & Co., and Lifecore Biomedical maintained their equal-weight rating.
Lifecore生物醫藥（納斯達克：LFCR）的最新分析師評級由史蒂芬斯及公司提供，Lifecore生物醫藥保持了他們的等權重評級。
When is the next analyst rating going to be posted or updated for Lifecore Biomedical (LFCR)?
Lifecore生物醫藥（LFCR）的下一個分析師評級將何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
分析師在進行廣泛研究後做出股票評級，其中包括查看公開的基本報表，與Lifecore生物醫藥的管理人員和客戶交談，以及收聽業績會議。大多數分析師每三個月進行一次評級，因此您每年應該能夠得到4個公司的每家公司的每家公司的評級。對於Lifecore生物醫藥的最新評級是在2023年9月1日提交的，因此您應該期待下一個評級在2024年9月1日左右發佈。
Is the Analyst Rating Lifecore Biomedical (LFCR) correct?
Lifecore生物醫藥（LFCR）的分析師評級是否準確？
While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a maintained with a price target of $8.00 to $9.00. The current price Lifecore Biomedical (LFCR) is trading at is $7.89, which is out of the analyst's predicted range.
雖然評級是主觀的且會變化，但最新的Lifecore生物醫藥（LFCR）評級是維持在8.00至9.00美元的目標價。當前價格Lifecore生物醫藥（LFCR）交易價格爲7.89美元，超出了分析師預測的區間。
譯文內容由第三人軟體翻譯。
